Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Compass Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

THE ANALYSES OF PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) REMAIN ON TRACK FOR LATE Q1 2026 IN THE ONGOING PHASE 2/3 COMPANION-002 STUDY OF TOVECIMIG (DLL4 X VEGF-A BISPECIFIC ANTIBODY) IN PATIENTS WITH ADVANCED BILIARY TRACT CANCER (BTC). IN THE ONGOING PHASE 1 DOSE-ESCALATION STUDY OF CTX-8371 (PD-1 X PD-L1 BISPECIFIC ANTIBODY), A PREVIOUSLY REPORTED THIRD RESPONSE HAS NOW BEEN CONFIRMED IN A PATIENT WITH HODGKIN LYMPHOMA (HL).

COMPASS THERAPEUTICS PROVIDES CORPORATE UPDATE

BOSTON, JAN. 05, 2026 (GLOBE NEWSWIRE) -- COMPASS THERAPEUTICS, INC. (NASDAQ: CMPX), A CLINICAL-STAGE, ONCOLOGY-FOCUSED BIOPHARMACEUTICAL COMPANY DEVELOPING PROPRIETARY ANTIBODY-BASED THERAPEUTICS TO TREAT MULTIPLE HUMAN DISEASES, TODAY ANNOUNCED IT GRANTED STOCK OPTIONS TO TWO NEW EMPLOYEES UNDER THE COMPANY'S 2025 INDUCEMENT PLAN AND AS A MATERIAL INDUCEMENT TO THEIR EMPLOYMENT IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

COMPASS ANNOUNCES INDUCEMENT GRANTS UNDERNASDAQ LISTING RULE 5635(C)(4)

BOSTON, JAN. 05, 2026 (GLOBE NEWSWIRE) -- COMPASS THERAPEUTICS, INC. (NASDAQ: CMPX), A CLINICAL-STAGE, ONCOLOGY-FOCUSED BIOPHARMACEUTICAL COMPANY DEVELOPING PROPRIETARY ANTIBODY-BASED THERAPEUTICS TO TREAT MULTIPLE HUMAN DISEASES, TODAY ANNOUNCED THE APPOINTMENTS OF ARJUN PRASAD, MBA, MPH AS CHIEF COMMERCIAL OFFICER AND CYNTHIA SIRARD, MD AS CHIEF MEDICAL OFFICER, BOTH EFFECTIVE AS OF JANUARY 1, 2026. WE ARE THRILLED TO WELCOME ARJUN AND CYNDI TO THE COMPASS TEAM.

COMPASS THERAPEUTICS ANNOUNCES KEY LEADERSHIP APPOINTMENTS

BOSTON, DEC. 17, 2025 (GLOBE NEWSWIRE) -- COMPASS THERAPEUTICS, INC. (NASDAQ: CMPX), A CLINICAL-STAGE, ONCOLOGY-FOCUSED BIOPHARMACEUTICAL COMPANY DEVELOPING PROPRIETARY ANTIBODY-BASED THERAPEUTICS, TODAY ANNOUNCED THAT THE COMPANY WILL PRESENT AT THE J.P. MORGAN 2026 HEALTHCARE CONFERENCE ON JANUARY 14, 2026.

COMPASS THERAPEUTICS TO PARTICIPATE IN THE J.P. MORGAN 2026 HEALTHCARE CONFERENCE

BOSTON, NOV. 25, 2025 (GLOBE NEWSWIRE) -- COMPASS THERAPEUTICS, INC. (NASDAQ: CMPX), A CLINICAL-STAGE, ONCOLOGY-FOCUSED BIOPHARMACEUTICAL COMPANY DEVELOPING PROPRIETARY ANTIBODY-BASED THERAPEUTICS, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN THE FOLLOWING INVESTOR EVENTS DURING THE MONTH OF DECEMBER.

COMPASS THERAPEUTICS TO PARTICIPATE IN UPCOMING DECEMBER INVESTOR EVENTS

BASED ON A CONTINUING TREND OF DECREASED MORTALITY IN THE ONGOING PHASE 2/3 COMPANION-002 STUDY OF TOVECIMIG (DLL4 X VEGF-A BISPECIFIC ANTIBODY) IN PATIENTS WITH ADVANCED BILIARY TRACT CANCER (BTC), THE ANALYSES OF OVERALL SURVIVAL (OS) AND PROGRESSION-FREE SURVIVAL (PFS) ARE EXPECTED IN LATE Q1 2026. A NEW RESPONSE IN A THIRD INDICATION HAS BEEN OBSERVED IN THE FIFTH AND FINAL DOSING COHORT OF THE PHASE 1 DOSE-ESCALATION STUDY OF CTX-8371 (PD-1 X PD-L1 BISPECIFIC ANTIBODY); NO DOSE-LIMITING TOXICITIES HAVE BEEN OBSERVED AT ANY DOSE LEVEL AND FULL TOPLINE DATA ARE NOW EXPECTED TO BE PRESENTED AT A MEDICAL MEETING IN H1 2026.

COMPASS THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

CTX-10726 DEMONSTRATED POTENT, SIMULTANEOUS INHIBITION OF TUMOR ANGIOGENESIS AND PD-1-MEDIATED IMMUNE SUPPRESSION, AND ELIMINATED TUMORS IN MULTIPLE PRECLINICAL STUDIES. IN VIVO, CTX-10726 OUTPERFORMED SELECT COMPETITIVE ANTIBODIES IN THE CLASS, INCLUDING IVONESCIMAB, IN CONTROLLING TUMOR GROWTH ACROSS MULTIPLE XENOGRAFT AND SYNGENEIC MODELS.

COMPASS THERAPEUTICS PRESENTS PRECLINICAL DATA ON CTX-10726, A DIFFERENTIATED PD-1 X VEGF-A BISPECIFIC ANTIBODY, AT THE 40TH SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING

BOSTON, NOV. 03, 2025 (GLOBE NEWSWIRE) -- COMPASS THERAPEUTICS, INC. (COMPASS) (NASDAQ: CMPX), A CLINICAL-STAGE, ONCOLOGY-FOCUSED BIOPHARMACEUTICAL COMPANY DEVELOPING PROPRIETARY ANTIBODY-BASED THERAPEUTICS TO TREAT MULTIPLE HUMAN DISEASES, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN THE FOLLOWING INVESTOR EVENTS DURING THE MONTH OF NOVEMBER. DETAILS ARE AS FOLLOWS: GUGGENHEIM 2ND ANNUAL HEALTHCARE INNOVATION CONFERENCE LOCATION: BOSTON, MA DATE: MONDAY, NOVEMBER 10, 2025 TIME: 3:30 PM ET WEBCAST LINK: HTTPS://EVENT.SUMMITCAST.COM/VIEW/6H3HS7Z68WNTQE5PS7VQ8J/WHRFP7V7J4XXPSB6WETMKP STIFEL 2025 HEALTHCARE CONFERENCE LOCATION: NEW YORK, NY DATE: WEDNESDAY, NOVEMBER 12, 2025 TIME: 4:00 PM ET WEBCAST LINK: HTTPS://EVENT.SUMMITCAST.COM/VIEW/CWKMPXKC4DOSG6MOG95RXB/PK2LUCFO5TANJQO7JVHDSB JEFFERIES GLOBAL HEALTHCARE CONFERENCE LOCATION: LONDON, UK DATE: THURSDAY, NOVEMBER 20, 2025 TIME: 12:00 PM GMT WEBCAST LINK: HTTPS://WSW.COM/WEBCAST/JEFF332/CMPX/1860808 VIRTUAL/REPLAY AVAILABILITY:PRESENTATIONS WILL BE ARCHIVED FOR 90 DAYS ON COMPASS' EVENTS PAGE.

COMPASS THERAPEUTICS TO PARTICIPATE IN UPCOMING NOVEMBER INVESTOR EVENTS

BOSTON, AUG. 26, 2025 (GLOBE NEWSWIRE) -- COMPASS THERAPEUTICS, INC. (COMPASS) (NASDAQ: CMPX), A CLINICAL-STAGE, ONCOLOGY-FOCUSED BIOPHARMACEUTICAL COMPANY DEVELOPING PROPRIETARY ANTIBODY-BASED THERAPEUTICS TO TREAT MULTIPLE HUMAN DISEASES, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN THE FOLLOWING INVESTOR EVENTS DURING THE MONTH OF SEPTEMBER.

COMPASS THERAPEUTICS TO PARTICIPATE IN UPCOMING SEPTEMBER INVESTOR EVENTS

BOSTON, AUG. 12, 2025 (GLOBE NEWSWIRE) -- COMPASS THERAPEUTICS, INC. (COMPASS) (NASDAQ: CMPX), A CLINICAL-STAGE, ONCOLOGY-FOCUSED BIOPHARMACEUTICAL COMPANY DEVELOPING PROPRIETARY ANTIBODY-BASED THERAPEUTICS TO TREAT MULTIPLE HUMAN DISEASES, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 33,290,000 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $3.00 PER SHARE AND PRE-FUNDED WARRANTS TO PURCHASE UP TO AN AGGREGATE OF 6,710,000 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $2.9999 PER PRE-FUNDED WARRANT TO PURCHASE ONE SHARE OF THE COMMON STOCK, WHICH REPRESENTS THE PER SHARE PUBLIC OFFERING PRICE FOR THE COMMON STOCK LESS THE $0.0001 PER SHARE EXERCISE PRICE FOR EACH SUCH PRE-FUNDED WARRANT. THE GROSS PROCEEDS FROM THE OFFERING TO COMPASS ARE EXPECTED TO BE APPROXIMATELY $120 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT AUGUST 14, 2025, SUBJECT TO CUSTOMARY CLOSING CONDITIONS. IN ADDITION, COMPASS HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO 6,000,000 ADDITIONAL SHARES OF COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS THE UNDERWRITING DISCOUNT.

COMPASS THERAPEUTICS ANNOUNCES PRICING OF UPSIZED $120 MILLION PUBLIC OFFERING

BOSTON, AUG. 12, 2025 (GLOBE NEWSWIRE) -- COMPASS THERAPEUTICS, INC. (COMPASS) (NASDAQ: CMPX), A CLINICAL-STAGE, ONCOLOGY-FOCUSED BIOPHARMACEUTICAL COMPANY DEVELOPING PROPRIETARY ANTIBODY-BASED THERAPEUTICS TO TREAT MULTIPLE HUMAN DISEASES, TODAY ANNOUNCED THE LAUNCH OF AN UNDERWRITTEN PUBLIC OFFERING OF ITS COMMON STOCK AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK. ALL SHARES OF COMMON STOCK AND PRE-FUNDED WARRANTS TO BE SOLD IN THE OFFERING WILL BE OFFERED BY COMPASS. COMPASS ALSO INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE ADDITIONAL SHARES OF ITS COMMON STOCK OFFERED IN THE PUBLIC OFFERING UNDER THE SAME TERMS AND CONDITIONS. THE OFFERING IS SUBJECT TO MARKET CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR THE ACTUAL SIZE OR TERMS OF THE OFFERING.

COMPASS THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING

BOSTON, AUG. 11, 2025 (GLOBE NEWSWIRE) -- COMPASS THERAPEUTICS, INC. (NASDAQ: CMPX), A CLINICAL-STAGE, ONCOLOGY-FOCUSED BIOPHARMACEUTICAL COMPANY DEVELOPING PROPRIETARY ANTIBODY-BASED THERAPEUTICS, TODAY REPORTED SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDED A BUSINESS UPDATE ON ITS CLINICAL AND PRE-CLINICAL PROGRAMS.

COMPASS THERAPEUTICS REPORTS 2025 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BOSTON, AUG. 08, 2025 (GLOBE NEWSWIRE) -- COMPASS THERAPEUTICS, INC. (NASDAQ: CMPX), A CLINICAL-STAGE, ONCOLOGY-FOCUSED BIOPHARMACEUTICAL COMPANY DEVELOPING PROPRIETARY ANTIBODY-BASED THERAPEUTICS, WILL RELEASE ITS FINANCIAL RESULTS FOR THE QUARTER ENDEDJUNE 30, 2025 AND HOST A WEBCAST AND CONFERENCE CALL TO PROVIDE AN UPDATE ON THE ONGOING TOVECIMIG PHASE 2/3 STUDY, CLINICAL DATA FOR CTX-8371 AND PRECLINICAL DATA FOR CTX-10726, ONMONDAY, AUGUST 11, 2025, AT8:00 A.M. ET.

Compass Therapeutics, Inc.

CMPX

Price

Financial Reports

No items found.

Press Releases

Compass Therapeutics, Inc.

CMPX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

CMPX